Clinical trials: Chronic Hepatitis Delta Virus Infection
Hepatitis B, Chronic, Hepatitis D
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
This is a randomized, double-blinded, placebo-controlled, multi center, dose ranging study of safety and efficacy in both volunteers with chronic hepatitis B virus infection and in volunteers with hepatitis D virus coinfection.
- Trial name
- NCT04847440
- Testing
- ATI-2173, Viread, AB-729
- Where
- 2 sites in Moldova, Ukraine
- Volunteers
- 40 people
- Sponsor
- Antios Therapeutics, Inc
Glucose Metabolism Disorders, Liver Fibrosis
Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents
Chronic hepatitis C infection is associated with changes of glucose metabolism end increased frequency of impaired glucose tolerance. This might be a additional risk factor for disease and fibrosis progression.
- Conditions
- Glucose Metabolism Disorders, Liver Fibrosis, Hepatitis C
- Trial name
- NCT03908294
- Testing
- Lab tests, non-invasive fibrosis (Fibroscan/ARFI)
- Where
- Germany
- Volunteers
- 46 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Hepatitis D
Lonafarnib for Chronic Hepatitis D
Background: Chronic hepatitis D is a severe disease of the liver caused by infection with the hepatitis D virus. The hepatitis D virus can only infect a person who also has hepatitis B; therefore, people with delta hepatitis have…
- Trial name
- NCT01495585
- Testing
- Lonafarnib
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)